metastatic pancreatic ductal carcinoma | sciencenewsnet.in

Breaking News

How one UIC student is proposing to advance science of superconductivity

Ensuring a bright future for diamond electronics and sensors

New Jersey Voters Rank Economy as No. 1 Issue, Followed by Immigration, Character and Reproductive Rights

Scientists’ ‘next-generation’ space materials blast off for tests on ISS

Explaining Science Through Dance

Selenium raised pharmaceutical value of garden sage

“The Southern Advanced Photon Source (SAPS)” by Prof. Hesheng Chen

Structural Safety Monitoring of Buildings with Color Variations

Meal timing may be crucial for night shift workers’ health

Out of Africa: UT Southwestern cardiologist gets to the heart of Zambia’s No. 1 health threat

05 Nov, 2024

New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer

November 11, 2020 sarah JonasResearch Results

New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.